Tara Lavelle
@tara_lavelle
Health Decision Scientist, Assistant Professor: @TuftsCEVR @TuftsMedicalCtr Boston, MA
Former: @RANDHealth, @UMchear, @HarvardGSAS
ID:1528832370
https://www.tuftsmedicalcenter.org/PhysicianDirectory/Tara-Lavelle 18-06-2013 21:08:44
1,8K Tweets
1,7K Followers
4,7K Following
NEW PUBLICATIONS IN HEALTH ECONOMICS AND GENOMICS 09/04/24
Two publications over the past week.
Link to blog: healtheconomicsandgenomics.com/2024/04/09/new…
#healtheconomics [1/3]
I'm presenting next week as part of the Queen Mary University of London Lifelong Health Seminar Series on 'Implementing genome sequencing in clinical practice across the life course: a health economics perspective'
April 16th, 1pm UK time
You can sign up here: qmul.ac.uk/fmd/research/m…
#healtheconomics
Nice day for the #CEVR2024 walk in the City of Boston. ☀️☀️☀️ The only things brighter than the sun were our sweatshirts! #SafetyFirst
My brilliant CEVR colleague Ching-Hsuan Lin: early rapid whole genome newborn screening saves money compared to conventional gene panel despite higher upfront costs. #cevr2024 Tara Lavelle
Planning a #healtheconomics course?
Visit the IHEA Teaching Repository to access course outlines and other teaching materials, or contribute your own to help enhance future courses!
Plus, don't miss IHEA's Teaching Skill Workshop videos on YouTube.
healtheconomics.org/teaching-mater…
I am hiring a postdoc to work on health econ topics related to Neurofibromatosis type 1 (NF1), a genetic tumor predisposition syndrome. 🧬 Work with a collaborative team of outcomes researchers and clinicians at CHeRP & Harvard hospitals. Apply here: tuftshealthplan.wd5.myworkdayjobs.com/THP/job/Boston…
📰New CEVR publication:
In an analysis on Medicare beneficiaries with dementia, Natalia Olchanski et al found that Medicare expenditures were higher for Black and Hispanic individuals compared with whites.
Read more: tinyurl.com/7wf9rj8s
Paige Lin
Yolanda Yingying Zhu
Howard Fillit, MD
In a new CEVR blog we used SPEC data to show that payers largely cover Accelerated Approval drugs in line with the FDA (with the exception of non-oncology drugs), calling into question how program reform will impact payer behavior cevr.tuftsmedicalcenter.org/news/despite-c… James Chambers
Delighted this important work on determining priority indicators of utility for genomic testing in rare disease is now published in Genetics in Medicine - Australian Genomics Economics of Genomics and Precision Medicine Unit